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Prolyl-4-hydroxylase α subunit 2 promotes breast
cancer progression and metastasis by regulating
collagen deposition
Gaofeng Xiong1, Lei Deng1, Jieqing Zhu1, Piotr G Rychahou1,2 and Ren Xu1,3*
Abstract
Background: Increased collagen deposition provides physical and biochemical signals to support tumor growth
and invasion during breast cancer development. Therefore, inhibition of collagen synthesis and deposition has
been considered a strategy to suppress breast cancer progression. Collagen prolyl-4-hydroxylase α subunit 2
(P4HA2), an enzyme hydroxylating proline residues in -X-Pro-Gly- sequences, is a potential therapeutic target for the
disorders associated with increased collagen deposition. However, expression and function of P4HA2 in breast
cancer progression are not well investigated.
Methods: Gene co-expression analysis was performed in the published microarray datasets to identify potential
regulators of collagen I, III, and IV in human breast cancer tissue. Expression of P4HA2 was silenced by shRNAs, and
its activity was inhibited by 1, 4-DPCA, a prolyl-4-hydroxylase inhibitor. Three-dimensional culture assay was used to
analyze roles of P4HA2 in regulating malignant phenotypes of breast cancer cells. Reduced deposition of collagen I
and IV was detected by Western blotting and immunofluorescence. Control and P4HA2-silenced breast cancer
cells were injected into fat pad and tail vein of SCID mice to examine effect of P4HA2 on tumor growth and lung
metastasis.
Results: Using gene co-expression analysis, we showed that P4HA2 was associated with expression of Col1A1,
Col3A1, and Col4A1 during breast cancer development and progression. P4HA2 mRNA levels were significantly
upregulated in breast cancer compared to normal mammary tissue. Increased mRNA levels of P4HA2 correlated with
poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status. Silencing P4HA2
expression or treatment with the P4HA inhibitor significantly inhibited cell proliferation and suppressed aggressive
phenotypes of breast cancer cells in 3D culture, accompanied by reduced deposition of collagen I and IV. We also
found that knockdown of P4HA2 inhibited mammary tumor growth and metastasis to lungs in xenograft models.
Conclusion: These results suggest the critical role of P4HA2 in breast cancer progression and identify P4HA2 as a
potential therapeutic target and biomarker for breast cancer progression.
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Background
Extracellular matrix (ECM) is an important component
of tumor microenvironment and plays critical roles in
cancer development [1-3]. Collagens are the major struc-
tural ECM proteins and form fibers or networks in tu-
mor tissue [4-6]. Cell-collagen interaction controls a
variety of cellular activities including proliferation, mi-
gration, and invasion through integrin and discoidin
domain receptor [7-9]. Enhanced expression and depos-
ition of collagens are associated with tumor development
and progression [10-12]. Recent studies demonstrate
that increased collagen deposition and crosslinking en-
hance the stiffness and density of mammary tissue
[5,10,13], which is an important risk factor for breast
cancer development. Type I collagen has been identified
as a prognosis marker and is associated with cancer re-
currence in human breast cancer patients [14]. Collagen
VI knockout mice have reduced primary tumor forma-
tion and growth [12], while enhancing collagen depos-
ition and inhibiting collagen degradation significantly
enhances tumor initiation and tumor growth [5,10]. In
addition, cancer cell invasion usually occurs at tumor-
stromal interfaces with oriented collagen fibers, and
aligned collagen fibers can facilitate cell migration and
metastasis [5,10,11,15]. These results indicate that in-
creased collagen expression and deposition promotes
breast cancer development and progression by enhan-
cing tumor growth and invasion. Therefore, inhibiting
collagen synthesis or deposition is a promising strategy
to suppress breast cancer progression.
Collagen biosynthesis is a multistep process that in-
volves several post-transcription modification enzymes,
and one of the most important members of these en-
zymes is collagen prolyl-4-hydroxylase [16]. It catalyzes
the formation of 4-hydroxyproline by hydroxylating pro-
line residues in -X-Pro-Gly- sequences [17-20]. Collagen
prolyl-4-hydroxylase resides within the lumen of the
endoplasmic reticulum (ER) [18] and its expression is
used as a marker for collagen synthesis [21,22]. Because
4-hydroxyproline residues formed in this reaction are
essential for triple helix formation and stabilization of
collagen [22-24], inhibiting the prolyl-4-hydroxylases ac-
tivity efficiently blocks collagen synthesis and deposition.
All known vertebrate collagen prolyl-4-hydroxylases are
α2β2 tetramers consisting of two α subunits and two β
subunits. Each α subunit contains the peptide substrate
binding domain and the two catalytic sites of the en-
zyme, and the β subunits have been identified as protein
disulfide isomerases [17,19,25]. Three types of collagen
prolyl-4-hydroxylases α isoforms (P4HA1, P4HA2 and
P4HA3) have been identified in human tissue. P4HA1 is
expressed in most cell types; P4HA2 is mainly expressed
in chondrocytes, osteoblasts, and capillary endothelial
cells; P4HA3 expression is detected in adult and fetal
tissues at very low levels compared to P4HA1 and P4HA2
[18,26]. Increased P4HA2 expression has been detected in
many solid tumors, including oral cavity squamous cell
carcinoma, papillary thyroid cancer, and breast cancer
[27-30], however, the function of P4HA2 in cancer pro-
gression largely remains to be determined.
Here, we showed that expression of P4HA2 and colla-
gen genes (Col1A1, Col3A1, and Col4A1) is significantly
correlated during breast cancer development and pro-
gression, and that increased mRNA levels of P4HA2 are
associated with poor prognosis in breast cancer patients.
Silencing P4HA2 or treatment with the P4HA inhibitor
attenuates cell proliferation and suppresses aggressive
3D phenotypes, tumor growth, and cancer metastasis,
which are accompanied by reduced collagen deposi-
tion. These results suggest that P4HA2 promotes breast
cancer progression by enhancing collagen deposition and




The Click-iT® EdU Alexa Fluor® 488 Imaging Kit and
Alexa Fluor® 594 phalloidin were from Invitrogen. Mat-
rigel (lrECM) and Type I collagen were from BD Bio-
science. ShP4HA2 plasmids were purchased from Sigma.
1, 4-DPCA was purchased from Cayman Chemical.
Masson’s trichrome stain kit was purchased from Poly-
sciences, Inc. The following antibodies were obtained as
indicated: integrin α6 (Millipore); collagen I (Abcam);
collagen IV (Abcam); P4HA2 (Santa Cruz); tubulin
(Millipore).
Cell culture and virus preparation
HMT-3522 T4-2 cells (a kind gift from Dr. Mina J.
Bissell) were maintained on tissue culture plastic as pre-
viously described [31]. MDA-MB-231 cells were propa-
gated in DMEM/F12 (Sigma) with 10% fetal bovine
serum (Invitrogen). MDA-MB-157 cells and ZR-75-1
cells were propagated in DMEM (Sigma) with 10% fetal
bovine serum. ZR-75-1 cells: ER-positive and PR posi-
tive; T4-2 cells, MDA-MB-231 cells and MDA-MB-157
cells: ER-negative and PR negative.
3D laminin-rich extracellular matrix (3D lrECM) on-
top cultures were prepared by trypsinization of cells
from tissue culture plastic, seeding of single cells on top
of a thin gel of Engelbreth-Holm-Swarm (EHS) tumor
extract (Matrigel: BD Biosciences, 354230), and addition
of medium containing 5% EHS. T4-2 cells were seeded
at a density of 2.1 × 104 cells per cm2; MDA-MB-157
cells, ZR-75-1 cells, and MDA-MB-231 cells were seeded
at 1.4 × 104 cells per cm2. T4-2 cells were maintained
in their propagation medium with media change every
2 days. MDA-MB-157 cells, ZR-75-1 cells and MDA-
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MB-231 cells were maintained in H14 medium with
1% fetal bovine serum. The cell colonies cultured in 3D
were imaged and used for immunofluorescence staining at
Day 4 after seeding.
HEK293 FT cells were transfected with scrambled




CAGAGACTGCTTTTTG) plus packaging lentivector
using lipofectamine (Invitrogen). Cancer cells were in-
fected with lentivirus and selected by puromycin 48 h after
infection.
Immunofluorescence and Masson’s trichrome staining
Cells in lrECM gel were smeared on slides, dried briefly,
and fixed with 4% paraformaldehyde and permeabilized
with 0.5% Triton X-100. Immunostaining was per-
formed as previous described [32]. Stained samples were
imaged with a Nikon upright epifluorescence microscope
or a confocal system comprised of an Olympus IX81
microscope.
Xenograft tumor sections were de-paraffined and hy-
drated from xylene, 100% ethanol, 95% ethanol, 85%
ethanol and 70% ethanol to distilled water. For Masson’s
trichrome staining, slides were re-fixed with Bouin’s so-
lution at 60°C for 60 minutes. Slides were washed in
running tap water for 5 minutes and stained in Weigert’s
working hematoxyin for 10 minutes. Then they were
washed in running tap water for 5 minutes and stained
in Biebrich scarlet-acid fuchsin solution for 5 minutes.
Slides were rinsed in distilled water and differentiated in
phosphomolybdic-phosphotungstic acid solution for 10
minutes, transferred to aniline blue solution and stain
for 5 minutes. Slides were rinsed in distilled water and
images were taken with a Nikon microscope. The per-
centage of collagen was quantified by calculating the ra-
tio of blue staining (collagen) area in the total area of
the tumor section using Imagescope analysis software
[33].
Western blot analysis
Cells grown on plastic were lysed in situ in 2% SDS in
PBS buffer containing phosphatase and protease inhi-
bitor cocktails (Calbiochem). Protein concentration was
measured using DC™ protein assay (Bio-Rad). Control
and shP4HA2 cells were trypsinized and counted; equal
amounts of conditional medium (normalized to cell
number) were precipitated by pre-cooled acetone. Equal
amounts of protein lysates and cell conditional medium
were subjected to SDS gel electrophoresis, immunoblot-
ted, and detected with an ECL system (Pierce). Western
blotting results were quantified using AlphaInnotech
analysis software.
Transwell invasion assay
The Transwells (Corning) were coated with 60 mL
1 mg/mL Matrigel and incubated for 30 minutes at
37°C. Sh-control or sh-P4HA2 silencing MDA-MB-
231 cells (1 × 105 cells in 200 μl medium) were plated
on the top of the Transwell filter and incubated in
37°C 5% CO2 for 24 h. The invaded cells on the bot-
tom face of the filter were fixed by methanol and
stained with 8% crystal violet. Images were taken with
a Nikon microscope and the number of invaded cells
was counted.
Xenograft experiment
Female SCID mice (6 weeks old) were randomly grouped
and injected with 2 × 106 sh-control or shP4HA2-1 MDA-
MB-231/Luc cells at mammary fat pad. Tumor volume
was measured using an in vivo imaging system (IVIS).
Tumors were measured with a caliper every 4 days for 6
weeks. At the experimental endpoint, tumors were har-
vested and fixed with 4% PFA for paraffin-embedded sec-
tion. All procedures were performed within the guidelines
of the Division of Laboratory Animal Resources at the
University of Kentucky.
Lung metastasis experiment
Female SCID mice (6 weeks old) were randomly grouped
and injected with 1 × 106 (in 200 μl PBS) sh-control or sh-
P4HA2-1 MDA-MB-231/Luc cells via tail vein. To detect
lung metastasis, bioluminescent images were taken day 30
after cancer cells injection with IVIS Spectrum. Mice were
sacrificed week 5 after cancer cells injection.
Kaplan Meier survival analysis and other statistical
analyses
Kaplan-Meier survival analysis was performed in a large
combined breast cancer dataset [34]. Breast cancer pa-
tients were grouped by estrogen receptor (ER)-positive
(n = 1452) and ER-negative (n = 473), and tumor samples
were equally grouped into low and high P4HA2 expres-
sion based on the mRNA levels. Significant differences
in overall survival time were assessed with the Cox pro-
portional hazard (log-rank) test.
Analysis of P4HA2 mRNA levels in normal and malig-
nant tissues was performed in the TCGA breast cancer
dataset that was downloaded from Oncomine. The asso-
ciation between mRNA levels of P4HA2 and collagen
genes was evaluated by the Spearman correlation ana-
lysis. All experiments were repeated at least twice. Re-
sults are reported as mean ± S.E.M; the significance of
difference was assessed by independent Student’s t-test.
P < 0.05 represents statistical significance and P < 0.01
represents sufficiently statistical significance. All reported
P values were 2-tailed. Statistical analysis was conducted
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with SigmaPlot (Systat Software, Inc.) and SAS (version
9.2; SAS Institute Inc.).
Results and discussion
P4HA2 is associated with collagen expression and poor
prognosis in human breast cancer
To determine which genes contribute to collagen depo-
sition during cancer development and progression, we
performed gene co-expression analysis using the pub-
lished microarray datasets generated from human breast
cancer tissues [35]. P4HA2 was identified as one of the
genes associated with ECM protein expression [35]. By
analyzing gene expression in the TCGA breast cancer
dataset downloaded from Oncomine, we found expres-
sion of Col1A1, Col3A1, and Col4A1 was significantly
correlated with P4HA2 levels in normal and malignant
breast tissues (p < 0.001, Figure 1A, B and C). Similar re-
sults were also obtained in another published microarray
dataset [36] (Additional file 1: Figure S1). To assess
whether P4HA2 expression is associated with breast can-
cer development and progression, we analyzed mRNA
levels of P4HA2 in the TCGA human breast cancer
Figure 1 P4HA2 is associated with collagen expression and poor prognosis in human breast cancer. (A-C) Scatterplot of correlated mRNA
levels between P4HA2 and (A) Col1A1, (B) Col3A1, and (C) Col4A1 in normal and malignant breast tissues (n = 593). The mRNA levels of P4HA2
were acquired from the TCGA microarray dataset generated from human breast cancer. (D) P4HA2 mRNA levels in IBC (invasive breast carcinoma)
(n = 76), IDBC (invasive ductal breast carcinoma) (n = 398) and ILBC (invasive lobular breast carcinoma) (n = 36) is higher than normal breast tissue
(n = 61). (E) P4HA2 mRNA expression is higher in ERBB2 (epidermal growth factor receptor 2) negative tumors than in ERBB2-positive cancer
tissues. (F) P4HA2 mRNA levels are associated with stages of breast cancer. (G) Kaplan-Meier survival analysis showed the association between
P4HA2 expression and clinical outcomes. Breast cancer patients were grouped by ER status (ER-positive, n = 1452; ER-negative, n = 473). Tumor
samples were classified into low and high P4HA2 expression based on the mRNA levels. Tumor had high P4HA2 expression levels in a shorter
overall survival period. The association of P4HA2 expression and clinical outcome is ER status independent (*p < 0.05; **p < 0.01; ***p < 0.001).
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microarray dataset. P4HA2 expression was significantly
upregulated in invasive breast carcinoma (p < 0.001), in-
vasive ductal breast carcinoma (p < 0.001) and invasive
lobular breast carcinoma (p < 0.001) compared to normal
breast tissue (Figure 1D). We also analyzed the associ-
ation of P4HA2 with a number of molecular markers of
breast cancer, such as ERBB2 (epidermal growth factor
receptor 2), ER, and PR. P4HA2 expression was signi-
ficantly upregulated in ERBB2-positive breast cancers
compared to ERBB2-negative breast cancers (p < 0.01)
(Figure 1E), but P4HA2 levels had no significant diffe-
rence between ER- or PR-positive and negative cancer
(data not shown). These data confirm the previous find-
ing that P4HA2 is associated with ERBB2 in human
breast cancer cells [29]. We also found that high stage
breast cancer had significantly increased P4HA2 ex-
pression (Figure 1F). These results indicate that breast
cancer development and progression is accompanied by
activation P4HA2, which may contribute to collagen
synthesis.
A number of genes encoding collagen proteins have
been identified as prognostic markers for human breast
cancer [37,38]. Since expression of P4HA2 and collagen
genes is correlated in human breast cancer tissues, we
asked whether P4HA2 expression is associated with cli-
nical outcome in human breast cancer patients. Breast
cancer patients were divided into two groups based on
P4HA2 mRNA levels (low and high). Kaplan-Meier log
rank analysis showed that patients whose tumors had
high P4HA2 expression levels had a significantly shorter
overall survival period (Figure 1G). Moreover, the associ-
ation of P4HA2 with clinical outcome is ER status inde-
pendent (see Figure 1G).
Inhibition of P4HA2 suppresses the malignant phenotypes
of breast cancer cells in 3D culture
Increased expression of P4HA2 has been detected in
many cancers [27-30], but roles of P4HA2 in cancer pro-
gression remain to be determined. To examine the func-
tion of P4HA2 in breast cancer progression, we silenced
P4HA2 expression in a panel of breast cancer cell lines
(HMT-3522 T4-2, MDA-MB-231, ZR-75-1, and MDA-
MB-157) with two different shRNAs (shP4HA2-1 and
shP4HA2-2). The P4HA2 knockdown efficiency in T4-2
cells was examined by Western blotting (Figure 2A). Si-
milar knockdown efficiency was also obtained in MDA-
MB-231 and ZR-75-1 cells (Additional file 1: Figure S2).
3D culture models have been widely used to examine
the malignant mammary tissue morphogenesis [31], and
the specific 3D phenotypes of breast cancer cells are as-
sociated with tumor development and cancer invasive-
ness. The breast cancer cell lines were classified into
four groups based on their phenotypes in 3D culture:
round, mass, grape-like, and stellate [39]. Malignant T4-2
cells usually form mass-like structures without apical-
basal polarity in Matrigel. Disruption of polarized acinar
structure is an early cellular event of tumor development,
and 3D culture of T4-2 cells has been used to monitor this
process. Knockdown of P4HA2 reprogrammed T4-2 cells
to form polarized spheroid structures with reduced colony
size (Figure 2B, C, D). Integrin α6 subunit has been used a
basal marker to detect basal polarity in mammary epithe-
lial cells [40,41]. Immunofluorescence staining of α6 integ-
rin showed that knockdown of P4HA2 reprogrammed the
T4-2 cells to form polarized acinar-like structures (basal
staining of α6 integrin), while the control cells formed the
unpolarized (lateral staining of α6 integrin) and mass-like
morphology (Figure 2B, C). Since disruption of polarized
acinar structure is an early event during breast cancer de-
velopment, these results suggest that P4HA2 contributes
to the early stage of breast cancer progression. Knock-
down of P4HA2 in T4-2 and ZR-75-1 cells also signifi-
cantly reduced colony size in 3D culture (Figure 2B, D).
To determine whether reduced colony size is due to
growth inhibition, cell proliferation was examined by
an EdU (5-ethynyl-2′-deoxyuridine) labeling assay as
described previously [42,43]. We found that EdU positive
cells were significantly reduced in P4HA2-silenced ZR-75-1
and T4-2 cells compared to control cells (Figure 2E).
MDA-MB-231 and MDA-MB-157 cells form stellate
structures in 3D culture, which reflects decreased cell-
cell interactions and enhanced cell invasiveness [39].
Silencing P4HA2 in MDA-MB-231 cells and MDA-
MB-157 cells significantly reduced invasive branches
compared to the control cells (Figure 3A, B). P4HA2-
silenced cells also had significantly reduced cell invasion
in the Transwell assay (Figure 3D, E). Surprisingly, knock-
down of P4HA2 had little effect on cell proliferation in
MDA-MB-231 in 3D culture system (Figure 3C). Thus,
P4HA2 activity in regulating cell proliferation may be can-
cer stage- and/or subtype-dependent. Nevertheless, re-
duced invasive branches in P4HA2-silenced cells indicate
that P4HA2 contributes to malignant tissue morphoge-
nesis and cancer cell invasion in 3D culture.
1,4 dihydrophenonthrolin-4-one-3-carboxylic acid
(1,4-DPCA) has been identified as a high efficiency
inhibitor of prolyl-4-hydroxylase [44-46]. To deter-
mine whether P4HA2 is a potential therapeutic target
for breast cancer, we treated breast cancer cells with
1,4-DPCA in 3D culture. 1,4-DPCA treatment signifi-
cantly reduced the colony sizes of T4-2 and ZR-75-1
cells (Figure 4A, B). Immunofluorescence staining re-
sults showed that 1,4-DPCA-treated T4-2 cells form
polarized spheroids in 3D culture (Figure 4C). Treat-
ment with 1,4-DPCA significantly reduced invasive
branches in MDA-MB-231 and MDA-MB-157 cells
(Figure 4A, D). Additionally, proliferation of T4-2,
ZR-75-1, MDA-MB-157 and MDA-MB-231 cells was
Xiong et al. BMC Cancer 2014, 14:1 Page 5 of 12
http://www.biomedcentral.com/1471-2407/14/1
all inhibited by 1,4-DPCA (Figure 4E). 1,4-DPCA is
not a P4HA2-specific inhibitor, and it also inhibits
activity of P4HA1 and P4HA3. A recent study shows
that P4HA1 and P4HA3 also contribute to breast cancer
progression [33]. Therefore, this small molecule may sup-
press the malignant phenotypes of breast cancer cells
in 3D culture by inhibiting all three P4HA isoforms.
Further investigation of 1,4-DPCA activity with an
in vivo mammary tumor model may lead to discovery
of a new drug to inhibit breast cancer development
and/or progression.
Daniele M. Gilkes et al. reported that knockdown of
P4HA2 or treatment MDA-MB-231 cells with hydroxy-
lase inhibitor DHB inhibits tumor growth in vivo, but
Figure 2 Silencing P4HA2 reduces colony size and proliferation of breast cancer cells in 3D culture. (A) P4HA2 knockdown efficiency in
T4-2 cells was verified by Western blot. (B) Phase images of control shRNA (shctrl) and shP4HA2-expressing ZR-75-1 and T4-2 cells in 3D culture
for 4 days. The right column shows immunofluorescence images of α6-integrin (green) and DAPI (blue) staining. P4HA2-silenced T4-2 cells formed
polarized acinar structures (arrows pointing to basal surface staining of α6-integrin), whereas control T4-2 cells still maintained disorganized
mass-like structures (arrows pointing to lateral staining of α6-integrin; scale bar, 50 μm). (C) Ratio of polarized colony in control and knockdown
P4HA2 T4-2 cells in 3D culture. (D) Quantification of colony size of control and P4HA2-silenced ZR-75-1 and T4-2 cells in 3D culture by measuring
the diameter of at least 50 colonies. Knockdown of P4HA2 decreased the colony size. (E) EdU-staining was used to analyze the proliferation of
control and P4HA2-silenced ZR-75-1 and T4-2 cells in 3D culture. Knockdown P4HA2 inhibited the proliferation of ZR-75-1 and T4-2 cells
(*p < 0.05; **p < 0.01).
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little inhibitory effect on cell proliferation was detected
in 2D culture assay [33]. 3D culture has been considered
a better model for testing drugs and investigating cancer
biology compared to 2D culture, and different drug re-
sponses between these two culture systems have recently
been reported [47-49]. For example, MDA-MB-231 cells
in 3D culture are more sensitive to MEK inhibition com-
pared to cells in 2D culture [47]. Using the 3D culture
model, we showed that reducing P4HA2 expression or
inhibiting its activity significantly inhibited cell prolifera-
tion and suppressed the malignant phenotypes in mul-
tiple breast cancer cell lines.
Figure 3 Knockdown of P4HA2 suppresses breast cancer cells invasiveness in 3D culture. (A) Phase images of control and P4HA2-silenced
MDA-MB-157 and MDA-MB-231 cells in 3D culture for 4 days. The right column shows immunofluorescence images of F-actin (red) and DAPI
(blue) staining. P4HA2-silenced MDA-MB-157 and MDA-MB-231 cells formed smaller and less invasive cell clusters than control cells (scale bar,
50 μm). (B) Quantification of the invasive branches of control and P4HA2-silenced MDA-MB-157 and MDA-MB-231 cells in 3D culture by counting
the branches in at least 50 colonies. Knockdown of P4HA2 reduced the invasive branches. (C) EdU-staining was used to analyze the proliferation
of control and P4HA2 knockdown MDA-MB-231 cells in 3D culture. Knockdown of P4HA2 had little effect on the proliferation of MDA-MB-231
cells (**p < 0.01). (D) Transwell cell invasion assay analysis of control and P4HA2-silenced MDA-MB-231 cells (scale bar, 200 μm). (E) Quantification
of invasion analysis of control and P4HA2-silenced MDA-MB-231 cells. Knockdown P4HA2 significantly inhibited cell invasion in MDA-MB-231 cells
compared with control group.
Xiong et al. BMC Cancer 2014, 14:1 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/1
Reducing P4HA2 expression or inhibiting its activity
impairs deposition of collagen I and IV
Since increased collagen deposition promotes tumor
progression by modulating tumor growth and invasion,
we asked whether P4HA2 regulates 3D malignant pheno-
types of breast cancer cells through enhancing colla-
gen expression and deposition. The conditioned medium
was collected from the control and P4HA2-silenced
cells (sh-P4HA2-1). Western blot analysis showed that
knockdown of P4HA2 in T4-2 cells reduced the pro-
tein levels of collagen I and IV in the condition me-
dium (Figure 5A). Deposition of collagen I and IV was
also reduced in the P4HA2-silenced and 1,4-DPCA-
treated T4-2 cells compared to the control T4-2 cell in 3D
culture (Figure 5B, C). These results indicate P4HA2 is
crucial for secretion and deposition of collagen I and IV in
T4-2 cells. Cancer cells produce a significant amount of
ECM proteins and remodeling enzymes [13,50-53]. Dr.
Massague’s group recently demonstrated that tenacin-c
produced by MDA-MB-231 cells enhances dissemination
and survival of tumor cells during the early steps of me-
tastasis by generating a metastatic niche [52]. In addition,
breast cancer cells express lysyl oxidases (LOXs), which
promote cell invasion by increasing tissue tension and
ECM rigidity [13,53]. These results indicate that the
ECM microenvironment remodeled by cancer cells is
Figure 4 Treatment with P4HA inhibitor attenuates breast cancer cell proliferation and invasiveness. (A) Phase images of control and
1,4-DPCA treated ZR-75-1 (20 μM 1,4-DPCA), T4-2 (10 μM 1,4-DPCA), MDA-MB-157 (20 μM 1,4-DPCA) and MDA-MB-231 (10 μM 1,4-DPCA) cells
in 3D culture. The cells treated with 1,4-DPCA formed smaller and less aggressive structures compared to control cells (scale bar, 50 μm).
(B) Quantification of colony size of control and 1,4-DPCA treated ZR-75-1 and T4-2 cells in 3D culture by measuring the diameter of at least 50
colonies. Treatment with 1,4-DPCA reduced the colony size. (C) Ratio of polarized colonies in control and 1,4-DPCA treated T4-2 cells in 3D
culture. (D) Quantification of the invaded branches of control and the 1,4-DPCA treated MDA-MB-157 and MDA-MB-231 cells in 3D culture by
measuring the branches in at least 50 colonies. Cells treated with 1,4-DPCA had decreased invasive branch number. (E) EdU-staining was used to
analyze the proliferation of control and the 1,4-DPCA treated ZR-75-1, T4-2, MDA-MB-157 and MDA-MB-231 cells in 3D culture. Treatment with
1,4-DPCA decreased proliferation of these four cell lines (*p < 0.05; **p < 0.01).
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critical for cancer progression. Thus, both inhibiting
P4HA2 activity and reducing its expression are poten-
tial strategies to suppress collagen-dependent cancer
progression.
P4HA2 regulates tumor growth and metastasis in vivo
Our data showed that silencing P4HA2 in breast cancer
cells suppressed their malignant phenotypes and in-
hibited cell proliferation in 3D culture. We also found
that P4HA2 expression is positively associated with
breast cancer progression, thus we hypothesized that
knockdown of P4HA2 reduces tumor growth and me-
tastasis in vivo. To test this hypothesis, we performed
xenograft tumor experiments using control and P4HA2-
silenced MDA-MB-231 cells. Knockdown of P4HA2
(sh-P4HA2-1) significantly inhibited primary tumor
growth in SCID mice (Figure 6A, B and C). HE stain-
ing showed that control group tumors had aggressive
invasion at primary tumor margins, while tumors in
the P4HA2-silenced (sh-P4HA2-1) group had no such
invasion (Figure 6D). Collagen deposition in the tumors
was assessed by Masson’s Trichrome staining. A sig-
nificant amount of collagen fibers was detected in the tu-
mors and at the tumor invasion margins in the control
group compared to the P4HA2-silenced (sh-P4HA2-1)
tumors (Figure 6E). It has been shown that increased
collagen deposition and/or orientation/alignment of colla-
gen fibers around tumors enhances cancer progression
[5,10,12,14]. Cancer cell invasion usually occurs at the
tumor-stromal interface with oriented collagen fibers, and
aligned collagen fibers can facilitate cell migration and
metastasis [5,10,15,54]. These results suggest that P4HA2
promotes tumor growth and invasion through enhancing
collagen deposition.
To determine whether P4HA2 promotes breast cancer
lung metastasis in vivo, the control and P4HA2-silenced
(sh-P4HA2-1) MDA-MB-231 cells were injected into the
tail veins of SCID mice. Lung colonization of the cancer
cells was monitored by IVIS imaging. We showed that
the mice injected with control cells developed lung me-
tastasis within 6 weeks, while no metastasis was detected
in the P4HA2-silenced group (Figure 6F). HE staining
Figure 5 Reducing P4HA2 expression or inhibiting its activity impairs collagen deposition. (A) Western blot analysis of collagen I and IV in
conditional media generated from the same amount of control and P4HA2-silenced (sh-P4HA2-1) T4-2 cells; bar graph shows quantification of
Western blot results (*p < 0.05; **p < 0.01) (B) Immunofluorescence staining of collagen I (green) and IV (green) in control and P4HA2-silenced
T4-2 cells. P4HA2 knockdown (sh-P4HA2-1) T4-2 cells showed impaired collagen I and IV protein deposition. (C) Immunofluorescence staining of
collagen I (green) and IV (green) in control and 1,4-DPAC treated T4-2 cells in 3D culture. T4-2 cells treated with 1,4-DPAC showed lower
expression of collagen I and IV (scale bar, 50 μm).
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further confirmed that knockdown of P4HA2 blocked
the lung colonization of MDA-MB-231 cells in SCID
mice (Figure 6G).
Conclusion
In the present study, we show that P4HA2 is associ-
ated with expression of collagen I, III, and IV during
breast cancer progression. Increased mRNA levels of
P4HA2 correlate with poor prognosis in human breast
cancer patients. Silencing P4HA2 or inhibiting its activity
suppresses breast cancer progression by reducing tumor
growth and metastasis, and this process is accompanied
by reduced collagen deposition. During preparation of
this manuscript, Daniele M. Gilkes et al. reported that
hypoxia-inducible factor 1 activates the transcription of
P4HA1 and 2 during breast cancer development, and this
activation enhances collagen fiber alignment and breast
cancer progression [33,55]. Taken together, these findings
indicate that P4HA2 is a promising therapeutic target to
inhibit ECM-dependent breast cancer progression.
Figure 6 Knockdown of P4HA2 suppresses tumor growth and metastasis in vivo. (A) Control or P4HA2-silenced (sh-P4HA2-1) MDA-MB-231/
Luciferase cells were injected into the mammary fat pad in SCID mice. IVIS images show representative mice from each group (n = 6). (B) Tumor
growth curve shows that knockdown of P4HA2 (sh-P4HA2-1) inhibited tumor growth in SCID mice (n = 6). (C) Tumor volume formed by p4HA2
knockdown (sh-P4HA2-1) cells was significantly reduced compared with control MDA-MB-231/Luc cells. Tumor volume was obtained by quantifying
IVIS images. (D) Tumor sections were stained with hematoxylin and eosin. Arrows point to invasion area at primary tumor margins (scale bar, 200 μm).
(E) Masson’s Trichrome staining of tumor sections (blue, collagen fibers; black, nuclei; red, cytoplasm). A significant amount of collagen fibers (arrows)
were detected in the control tumors, but not in the P4HA2-silenced (sh-P4HA2-1) tumors (scale bar, 200 μm). The right bar graph is the quantification
of Masson’s Trichrome staining results. (F) Mice received a tail vein injection of control or P4HA2 knockdown (sh-P4HA2-1) MDA-MB-231/Luc cells
(n = 5). IVIS image showed lung metastasis of control and P4HA2-silenced (sh-P4HA2-1) MDA-MB-231 cells in SCID mice. Lung metastasis can be
detected in control but not in the knockdown P4HA2 group (*p < 0.05). (G) Lung colonization was analyzed by hematoxylin and eosin staining.
Arrows point to the tumor formed in control group lung tissue (Scale bar, 500 μm).
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Additional file
Additional file 1: Figure S1. Scatterplot of correlated mRNA levels
between P4HA2 and (A) Col1A1, (B) Col3A1 and (C) Col4A1. Plots indicate
the correlation between P4HA2 and Col1A1, Col3A1, Col4A1 expression in
malignant breast tissues (n=118). The mRNA levels of P4HA2 were
acquired from the Chin K’s breast cancer dataset [36]. Figure S2. Five
shP4HAs were tested in MDA-MB-231 cells by Western blot. ShP4HA2-1
and shP4HA2-2 showed best knockdown efficiency. Figure S3. Western
blotting experiments shown P4HA2 knock out efficiency in shP4HA2-1
and shP4HA2-2 infected ZR-75-1 cells and MDA-MB-157 cells.
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